Prevention of opportunistic infections in HIV infection by pentoxiphylline

Ajay Wanchu, A. Bhatnagar, P. Bambery, S. Singh, S. Varma

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background & objectives: Levels of tumour necrosis factor (TNF) are increased in patients with HIV infection leading to increased apoptosis and reduced CD4 cell life. Pentoxiphylline is a TNF inhibitor with properties that might make it useful for the treatment of HIV infection. These include improved cell mediated immunity and inhibition of viral replication. We carried out this study to determine the therapeutic utility of pentoxiphylline in improving constitutional manifestations, preventing opportunistic infections and sustaining CD4 counts among asymptomatic HIV infected individuals (i.e., those with no opportunistic infection). Methods: Individuals with HIV infection who were over 18 yr of age and free of opportunistic infections were recruited in the study and followed up 4 weekly. CD4 counts were measured using a flowcytometer using anti-human CD4 intervals. Pentoxiphylline was prescribed in a dose of 400 mg thrice daily. Results: Thirty three (18 males) patients with HIV infection were studied. During their follow up (mean 12.5 ± 5.6 months) one patient each developed cryptococcal meningitis and fibrocavitary tuberculosis. Weight increased from 51.3 ± 7.4 kg at baseline to 55.3 ± 7.4 kg (P3 at four weeks (P

Original languageEnglish (US)
Pages (from-to)705-708
Number of pages4
JournalIndian Journal of Medical Research
Volume124
Issue numberDEC.
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Opportunistic Infections
HIV Infections
Tumor Necrosis Factor-alpha
CD4 Lymphocyte Count
Apoptosis
Cryptococcal Meningitis
Cellular Immunity
Tuberculosis
HIV
Weights and Measures
Therapeutics

Keywords

  • Anti-TNF therapy
  • HIV
  • Opportunistic infections
  • Pentoxiphylline

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Wanchu, A., Bhatnagar, A., Bambery, P., Singh, S., & Varma, S. (2006). Prevention of opportunistic infections in HIV infection by pentoxiphylline. Indian Journal of Medical Research, 124(DEC.), 705-708.

Prevention of opportunistic infections in HIV infection by pentoxiphylline. / Wanchu, Ajay; Bhatnagar, A.; Bambery, P.; Singh, S.; Varma, S.

In: Indian Journal of Medical Research, Vol. 124, No. DEC., 12.2006, p. 705-708.

Research output: Contribution to journalArticle

Wanchu, A, Bhatnagar, A, Bambery, P, Singh, S & Varma, S 2006, 'Prevention of opportunistic infections in HIV infection by pentoxiphylline', Indian Journal of Medical Research, vol. 124, no. DEC., pp. 705-708.
Wanchu A, Bhatnagar A, Bambery P, Singh S, Varma S. Prevention of opportunistic infections in HIV infection by pentoxiphylline. Indian Journal of Medical Research. 2006 Dec;124(DEC.):705-708.
Wanchu, Ajay ; Bhatnagar, A. ; Bambery, P. ; Singh, S. ; Varma, S. / Prevention of opportunistic infections in HIV infection by pentoxiphylline. In: Indian Journal of Medical Research. 2006 ; Vol. 124, No. DEC. pp. 705-708.
@article{d6fd30b96fb741e58c53d1254732d376,
title = "Prevention of opportunistic infections in HIV infection by pentoxiphylline",
abstract = "Background & objectives: Levels of tumour necrosis factor (TNF) are increased in patients with HIV infection leading to increased apoptosis and reduced CD4 cell life. Pentoxiphylline is a TNF inhibitor with properties that might make it useful for the treatment of HIV infection. These include improved cell mediated immunity and inhibition of viral replication. We carried out this study to determine the therapeutic utility of pentoxiphylline in improving constitutional manifestations, preventing opportunistic infections and sustaining CD4 counts among asymptomatic HIV infected individuals (i.e., those with no opportunistic infection). Methods: Individuals with HIV infection who were over 18 yr of age and free of opportunistic infections were recruited in the study and followed up 4 weekly. CD4 counts were measured using a flowcytometer using anti-human CD4 intervals. Pentoxiphylline was prescribed in a dose of 400 mg thrice daily. Results: Thirty three (18 males) patients with HIV infection were studied. During their follow up (mean 12.5 ± 5.6 months) one patient each developed cryptococcal meningitis and fibrocavitary tuberculosis. Weight increased from 51.3 ± 7.4 kg at baseline to 55.3 ± 7.4 kg (P3 at four weeks (P",
keywords = "Anti-TNF therapy, HIV, Opportunistic infections, Pentoxiphylline",
author = "Ajay Wanchu and A. Bhatnagar and P. Bambery and S. Singh and S. Varma",
year = "2006",
month = "12",
language = "English (US)",
volume = "124",
pages = "705--708",
journal = "Indian Journal of Medical Research",
issn = "0971-5916",
publisher = "Indian Council of Medical Research",
number = "DEC.",

}

TY - JOUR

T1 - Prevention of opportunistic infections in HIV infection by pentoxiphylline

AU - Wanchu, Ajay

AU - Bhatnagar, A.

AU - Bambery, P.

AU - Singh, S.

AU - Varma, S.

PY - 2006/12

Y1 - 2006/12

N2 - Background & objectives: Levels of tumour necrosis factor (TNF) are increased in patients with HIV infection leading to increased apoptosis and reduced CD4 cell life. Pentoxiphylline is a TNF inhibitor with properties that might make it useful for the treatment of HIV infection. These include improved cell mediated immunity and inhibition of viral replication. We carried out this study to determine the therapeutic utility of pentoxiphylline in improving constitutional manifestations, preventing opportunistic infections and sustaining CD4 counts among asymptomatic HIV infected individuals (i.e., those with no opportunistic infection). Methods: Individuals with HIV infection who were over 18 yr of age and free of opportunistic infections were recruited in the study and followed up 4 weekly. CD4 counts were measured using a flowcytometer using anti-human CD4 intervals. Pentoxiphylline was prescribed in a dose of 400 mg thrice daily. Results: Thirty three (18 males) patients with HIV infection were studied. During their follow up (mean 12.5 ± 5.6 months) one patient each developed cryptococcal meningitis and fibrocavitary tuberculosis. Weight increased from 51.3 ± 7.4 kg at baseline to 55.3 ± 7.4 kg (P3 at four weeks (P

AB - Background & objectives: Levels of tumour necrosis factor (TNF) are increased in patients with HIV infection leading to increased apoptosis and reduced CD4 cell life. Pentoxiphylline is a TNF inhibitor with properties that might make it useful for the treatment of HIV infection. These include improved cell mediated immunity and inhibition of viral replication. We carried out this study to determine the therapeutic utility of pentoxiphylline in improving constitutional manifestations, preventing opportunistic infections and sustaining CD4 counts among asymptomatic HIV infected individuals (i.e., those with no opportunistic infection). Methods: Individuals with HIV infection who were over 18 yr of age and free of opportunistic infections were recruited in the study and followed up 4 weekly. CD4 counts were measured using a flowcytometer using anti-human CD4 intervals. Pentoxiphylline was prescribed in a dose of 400 mg thrice daily. Results: Thirty three (18 males) patients with HIV infection were studied. During their follow up (mean 12.5 ± 5.6 months) one patient each developed cryptococcal meningitis and fibrocavitary tuberculosis. Weight increased from 51.3 ± 7.4 kg at baseline to 55.3 ± 7.4 kg (P3 at four weeks (P

KW - Anti-TNF therapy

KW - HIV

KW - Opportunistic infections

KW - Pentoxiphylline

UR - http://www.scopus.com/inward/record.url?scp=34247166603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247166603&partnerID=8YFLogxK

M3 - Article

C2 - 17287559

AN - SCOPUS:34247166603

VL - 124

SP - 705

EP - 708

JO - Indian Journal of Medical Research

JF - Indian Journal of Medical Research

SN - 0971-5916

IS - DEC.

ER -